Statistics from Altmetric.com
We read with great interest the article entitled ‘Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers’ by Pfefferkorn et al.1 Serum hepatitis B surface antigen (HBsAg) level has been shown to complement HBV DNA level in predicting clinical outcomes of patients with chronic HBV infection.2 3 In Asian patients, mostly genotype B and C infection, with a low viral load (HBV DNA ≤2000 IU/mL), HBsAg level >1000 IU/mL indicates …
Contributors HHL and TCT drafted the manuscript. JHK did the critical review of the manuscript.
Funding This work was supported by the grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST 105-2314-B-303-008).
Competing interests JHK is the consultant for Abbvie, Bristol-Myers Squibb and Gilead Sciences; on speaker’s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences and Merck.
Patient consent Obtained.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.